These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 20970309)
1. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy. Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309 [TBL] [Abstract][Full Text] [Related]
2. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699 [TBL] [Abstract][Full Text] [Related]
3. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847 [TBL] [Abstract][Full Text] [Related]
4. Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells. Hashimoto O; Shimizu K; Semba S; Chiba S; Ku Y; Yokozaki H; Hori Y Pathobiology; 2011; 78(4):181-92. PubMed ID: 21778785 [TBL] [Abstract][Full Text] [Related]
5. [Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy]. Cai C; Wang J; Zhong Z; Dai Z; Wang Q; Dong W; Shi H; Liu Q; DU J Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):36-43. PubMed ID: 28436629 [TBL] [Abstract][Full Text] [Related]
6. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival. Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Morimoto Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M Oncol Rep; 2010 Aug; 24(2):345-50. PubMed ID: 20596619 [TBL] [Abstract][Full Text] [Related]
8. CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1α (HIF-1α). Sun C; Song H; Zhang H; Hou C; Zhai T; Huang L; Zhang L J Cancer Res Clin Oncol; 2012 Oct; 138(10):1619-24. PubMed ID: 22614155 [TBL] [Abstract][Full Text] [Related]
9. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Hashimoto K; Aoyagi K; Isobe T; Kouhuji K; Shirouzu K Gastric Cancer; 2014 Jan; 17(1):97-106. PubMed ID: 23558457 [TBL] [Abstract][Full Text] [Related]
13. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Matsumoto K; Arao T; Tanaka K; Kaneda H; Kudo K; Fujita Y; Tamura D; Aomatsu K; Tamura T; Yamada Y; Saijo N; Nishio K Cancer Res; 2009 Sep; 69(18):7160-4. PubMed ID: 19738050 [TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143 [TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652 [TBL] [Abstract][Full Text] [Related]
16. Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia. Zhu H; Wang D; Zhang L; Xie X; Wu Y; Liu Y; Shao G; Su Z Oncol Rep; 2014 Sep; 32(3):935-42. PubMed ID: 24994549 [TBL] [Abstract][Full Text] [Related]
17. Immunohistological expression of HIF-1α, GLUT-1, Bcl-2 and Ki-67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer. Havelund BM; Sørensen FB; Pløen J; Lindebjerg J; Spindler KL; Jakobsen A APMIS; 2013 Feb; 121(2):127-38. PubMed ID: 23030583 [TBL] [Abstract][Full Text] [Related]
18. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Inoue Y; Miki C; Kusunoki M Ann Surg Oncol; 2010 Aug; 17(8):2051-8. PubMed ID: 20177796 [TBL] [Abstract][Full Text] [Related]
19. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046 [TBL] [Abstract][Full Text] [Related]
20. hypoxia-inducible factors activate CD133 promoter through ETS family transcription factors. Ohnishi S; Maehara O; Nakagawa K; Kameya A; Otaki K; Fujita H; Higashi R; Takagi K; Asaka M; Sakamoto N; Kobayashi M; Takeda H PLoS One; 2013; 8(6):e66255. PubMed ID: 23840432 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]